DP ARF ULTRASOUND - Double Push Acoustic Radiation Force Ultrasound for Monitoring Degeneration

Frequently Asked Questions (FAQs) about this study:


What stage is this research?

  • This study is active, but no longer recruiting participants.


What is the goal or purpose of this study?

  • This is a pilot clinical trial to assess the ability of a new ultrasound-based imaging method, Double-Push Acoustic Radiation Force (DP ARF) ultrasound, to monitor the progression of Duchenne muscular dystrophy.


Who is sponsoring this study?

  • This study is sponsored by the University of North Carolina, Chapel Hill, in collaboration with the National Institute of Neurological Disorders and Glossary Link Stroke (NINDS).


Who is eligible to participate in this study?

  • The study population includes 30 boys with Duchenne enrolling at ages 5 to 10 years. To be considered for enrollment, boys must have had a clinical onset of Duchenne by age 5. Male siblings with no known neuromuscular disorders, ages 5 to 10 years, were also eligible for enrollment as controls.


What are participants doing in this study?

  • All boys will be imaged 3 times annually for 4 years. In addition to DP ARF imaging every 4 months, the boys will undergo standard quantitative muscle testing (QMT) and timed function tests (TFT) of time to standing, 6-minute walk, and 30-feet walk. Age at loss of ambulation will also be recorded for each boy.


Where does this study take place?

  • This study takes place at the University of North Carolina, Chapel Hill (UNC-CH).


When can I expect to hear results from this study?

  • The researchers will be collecting data through August 2017, and then they will be processing the data and interpreting the results for several months.


Where can I learn more about this study?


(Updated 4/18/2017)